γγThe preservation of reproductive function is only applicable to endometrioid adenocarcinoma, while endometrial plasmacytoma, clear cell carcinoma and carcinosarcoma cannot preserve reproductive function. Specifically, fertility preservation is only possible if all of the following conditions are met and the treatment process is strictly adhered to: (1) the pathological type of endometrioid adenocarcinoma is highly differentiated as verified by pathologists in the segmental scrapings; (2) the lesion is confined to the endometrium as detected by magnetic resonance imaging (MRI) (preferred) or transvaginal ultrasound; (3) no suspicious metastatic lesion is detected by imaging; (4) there is no contraindication to drug therapy or pregnancy; (5) the lesion is not detected by imaging (4) No contraindications to drug therapy or pregnancy; (5) Adequate consultation to understand that preservation of fertility is not the standard of care for endometrial cancer. (6) Genetic counseling or genetic testing for suitable patients; (7) Methoprene, medroxyprogesterone acetate and levonorgestrel intrauterine delayed-release system are available; (8) Segmental scraping or endometrial biopsy every 3-6 months during the treatment period; if endometrial cancer persists for 6-9 months, total hysterectomy + bilateral adnexal resection + surgical staging is performed; if after 6 months If the lesion is in complete remission after 6 months, the patient should be encouraged to conceive and endometrial sampling should be performed every 3-6 months before pregnancy.γγ(10) Each patient should be fully informed of the possible risks and treatment effects during treatment and sign an informed consent form before treatment.